New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareMelanotan II vs Bronchogen

Melanotan II vs Bronchogen

Side-by-side comparison of key properties, dosing, and research.

Sexual Health & Libido
Melanotan II
Anti-Aging & Longevity
Bronchogen
Summary
Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) that stimulates melanin production (skin tanning), suppresses appetite, and enhances sexual function. It is not FDA-approved and has significant safety concerns including mole changes and cardiovascular effects.
Bronchogen is a tetrapeptide bioregulator (Ala-Glu-Asp-Leu) developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It is a tissue-specific bioregulator designed for the bronchi and lungs, promoting normalization of bronchial epithelial cell function. Research suggests benefits for respiratory health, protection against pulmonary aging, and support for bronchopulmonary conditions.
Half-Life
1–2 hours
Short (minutes to hours); bioregulator effects are gene-mediated and longer lasting
Admin Route
SubQ
SubQ, Oral
Research
Typical Dose
0.25–0.5 mg
10 mg per day
Frequency
Once daily
Daily for 10–30 days
Key Benefits
  • Promotes skin tanning and melanin production
  • Reduces UV exposure needed to tan
  • Enhances libido and sexual function
  • May suppress appetite
  • Faster, deeper tan development
  • Longer-lasting tan maintenance
  • Potential photoprotective effects
  • Tissue-specific support for bronchial and lung health
  • Promotes normalization of bronchial epithelial cell function
  • Potential benefits in chronic bronchitis and COPD support
  • Anti-aging effects on pulmonary tissue
  • May reduce frequency of respiratory infections
  • Supports lung function preservation with aging
  • Compatible with other Khavinson bioregulator peptides
Side Effects
  • Nausea (very common, especially in first days)
  • Facial flushing
  • Spontaneous erections in men
  • Darkening or changes in existing moles (monitor closely)
  • +3 more
  • Generally well tolerated in research studies
  • Mild local reactions at injection site (if injected)
  • No significant systemic side effects reported at standard doses
Stacks With